Phosphate Binders
On this page
Direct answer
Phosphate binders work only when swallowed with the phosphate: taken during meals, calcium carbonate, calcium acetate, sevelamer, lanthanum and iron-based agents complex dietary phosphate in the gut lumen and carry it out unabsorbed. Dialysis-stage patients typically need one to two binder tablets per meal plus dietary restriction, titrated toward the roughly 3.5-5.5 mg/dL phosphate range used in practice. Calcium-based binders are the affordable Indian backbone: calcium carbonate is 40% elemental calcium with a 1500 mg daily cap on binder-derived elemental calcium, and calcium acetate binds more phosphate per milligram of calcium delivered. Non-calcium options matter when calcium is high or calcification is present: sevelamer carbonate lowers phosphate and LDL cholesterol but seizes levothyroxine and ciclosporin unless doses are spaced; ferric citrate and sucroferric oxyhydroxide bind iron-handedly with fewer tablets; aluminium hydroxide is restricted to brief courses because chronic use causes the aluminium toxicity triad of adynamic bone disease, dialysis encephalopathy and microcytic anaemia.
What you must remember
- The timing rule: binders are taken with meals and snacks containing phosphate — a binder swallowed between meals binds nothing; non-adherence tracks pill burden above all.
- Calcium carbonate: cheap, 40% elemental calcium, acid-dependent (less effective with proton pump inhibitors); calcium acetate 25% elemental but binds more phosphate per unit calcium — widely stocked in Indian pharmacies.
- Calcium cap: limit binder-derived elemental calcium to about 1500 mg daily; avoid calcium-based binders entirely with hypercalcaemia, arterial calcification or suppressed parathyroid hormone.
- Sevelamer carbonate 800 mg: non-absorbed polymer, 1-2 tablets per meal titrated to phosphate; lowers LDL as collateral; reduces absorption of levothyroxine, ciclosporin and ciprofloxacin — separate dosing by hours.
- Lanthanum carbonate: chewable with meals, effective with low pill count; gastrointestinal effects dominate.
- Iron-based binders: ferric citrate (adds absorbed iron — watch ferritin) and sucroferric oxyhydroxide 500 mg once or twice daily — the fewest tablets in the class.
- Aluminium hydroxide: effective but aluminium toxicity — adynamic bone disease, dialysis encephalopathy, microcytic anaemia — restricts it to short courses in refractory hyperphosphataemia.
- Whole-bone-package monitoring: phosphate toward 3.5-5.5 mg/dL, corrected calcium, and intact parathyroid hormone held roughly two to nine times the assay upper limit on dialysis per KDIGO.
A dialysis phosphate problem, unwound
A 54-year-old on maintenance haemodialysis returns with phosphate 7.2 mg/dL despite calcium carbonate 1 g with each meal, corrected calcium 10.4 mg/dL, and intact parathyroid hormone within target. The audit proceeds in order: first the dietitian revisits — the phosphate load from dairy, nuts and processed foods with phosphate additives is invisible to patients; second the technique — is he chewing the tablets with the first bite, since post-meal swallowing wastes the dose; third the calcium ledger — he is already at 1200 mg elemental calcium, near the cap, with a calcium drifting high. The correct escalation is therefore non-calcium: sevelamer carbonate 800 mg, two tablets per meal, titrated against monthly phosphate — with levothyroxine moved to bedtime, four hours from any binder.
Two months later the phosphate sits at 5.3 mg/dL and his LDL has fallen a bonus 18 mg/dL. Had his phosphate stayed stubborn at 7 with correct technique and sevelamer at full dose, a short aluminium-hydroxide course would be next — brief, monitored, abandoned the moment the target is met, because the aluminium syndromes were the price earlier dialysis generations paid.
Where students slip
The timing question is nearly free marks and still missed: binders go with food, and a stem describing perfect adherence "one hour after meals" describes a failed regimen. The second slip is calcium arithmetic — candidates forget that 1 g of calcium carbonate carries 400 mg of elemental calcium, and that the cap counts binder calcium alone; a hypercalcaemia stem on calcium carbonate points straight to the cap being breached. Third, interaction spacing: sevelamer with levothyroxine, ciclosporin or ciprofloxacin reduces their absorption — the answer is separation, not substitution. Finally, the aluminium triad — adynamic bone, encephalopathy, microcytic anaemia — appears as a set in options; a dialysis stem pairing chronic binder use with dementia or a microcytic picture expects aluminium.
Frequently asked questions
When are phosphate binders taken?
With meals and phosphate-containing snacks — they complex dietary phosphate in the gut lumen, so timing with food is the entire mechanism of action.
Why is elemental calcium from binders capped near 1500 mg daily?
To limit iatrogenic hypercalcaemia and vascular calcification, especially when calcium-based binders are combined with vitamin D analogues in dialysis patients.
What makes sevelamer different from calcium-based binders?
It is a non-absorbed, calcium-free polymer that also lowers LDL cholesterol, but it binds co-administered drugs — levothyroxine, ciclosporin, ciprofloxacin — so dosing must be separated.
Why is aluminium hydroxide no longer used long-term?
Chronic aluminium exposure causes adynamic bone disease, dialysis encephalopathy and microcytic anaemia — it survives only as short-course rescue therapy for refractory hyperphosphataemia.
What phosphate target guides titration in dialysis patients?
Practice commonly titrates toward the roughly 3.5-5.5 mg/dL range, alongside corrected calcium and parathyroid hormone held about two to nine times the assay upper limit per KDIGO guidance.